Management Comments on Thursday Could Boost Shares of Alexion (ALXN)

Deutsche Bank today maintained a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) with a price target of $117.00. Analyst Robyn Karnauskas said management plans to provide investors with an update on Rhode Island manufacturing during Thursday's quarterly call, which could provide a catalyst for shares.

"We expect Rhode Island to be a key source of questions & proactive discussion by Alexion on quarterly call. In speaking to mgmt, we understand that Alexion has done a lot of work to address manufacturing issues included in warning letter since August. We think if Alexion addresses concerns on call that this might provide some support to shares, which have been weak (likely around this matter)," said Karnauskas.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals (NASDAQ: ALXN) click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $92.60 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• DA Davidson Reiterates Neutral Rating on Timken (TKR)